Patents by Inventor Ella Ioffe

Ella Ioffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240316361
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.
    Type: Application
    Filed: April 24, 2024
    Publication date: September 26, 2024
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Patent number: 12024570
    Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: July 2, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston, William Olson
  • Publication number: 20240166740
    Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Application
    Filed: May 15, 2023
    Publication date: May 23, 2024
    Inventors: Erica ULLMAN, Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON
  • Publication number: 20240138384
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Application
    Filed: January 16, 2024
    Publication date: May 2, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Patent number: 11910788
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: February 27, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Publication number: 20230279070
    Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy.
    Type: Application
    Filed: April 28, 2023
    Publication date: September 7, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jie DAI, Maria del Pilar MOLINA-PORTELA, Ella IOFFE, Markus MOHRS
  • Publication number: 20230235089
    Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to immunomodulatory receptor cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in combination with a therapeutically effective amount of a bispecific antibody that specifically binds Mucin 16 (MUC16) and CD3.
    Type: Application
    Filed: November 23, 2022
    Publication date: July 27, 2023
    Inventors: Ella Ioffe, Elena Burova
  • Patent number: 11692032
    Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: July 4, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Erica Ullman, Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston
  • Patent number: 11673930
    Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy. IL10 agonists disclosed herein comprise an IgG Fc domain, a linker moiety, and an IL10 moiety.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: June 13, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Jie Dai, Maria del Pilar Molina-Portela, Ella Ioffe, Markus Mohrs
  • Publication number: 20210380702
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Application
    Filed: August 11, 2021
    Publication date: December 9, 2021
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Publication number: 20210355184
    Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy.
    Type: Application
    Filed: May 11, 2021
    Publication date: November 18, 2021
    Inventors: Jie DAI, Maria del Pilar MOLINA-PORTELA, Ella IOFFE, Markus MOHRS
  • Patent number: 11117970
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: September 14, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Publication number: 20210161112
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Application
    Filed: January 29, 2021
    Publication date: June 3, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Patent number: 10939673
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: March 9, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Publication number: 20210040232
    Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
    Type: Application
    Filed: October 14, 2020
    Publication date: February 11, 2021
    Inventors: Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON, William OLSON
  • Patent number: 10844137
    Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 24, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston, William Olson
  • Publication number: 20200330794
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.
    Type: Application
    Filed: July 2, 2020
    Publication date: October 22, 2020
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Patent number: 10737113
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: August 11, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Patent number: 10532096
    Abstract: The present invention provides pharmaceutical compositions comprising a VEGF antagonist and an anti-CTLA-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: January 14, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Ella Ioffe, Israel Lowy, Gavin Thurston, Elena Burova
  • Publication number: 20190284277
    Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Application
    Filed: June 6, 2019
    Publication date: September 19, 2019
    Inventors: Erica ULLMAN, Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON